Chemists ID possible addiction-free pain reliever

pain
Credit: CC0 Public Domain

An estimated 1.7 million Americans suffer from substance abuse disorders related to opioid use for pain relief, according to the National Institute on Drug Abuse. This causes an economic burden of more than $78 billion per year in health care and addiction treatment costs, as well as loss of worker productivity and increased criminal activity. In 2017, more than 47,000 people died as a result of drug abuse involving opioids and related drugs.

As the problem amplifies, researchers are seeking non-addictive chronic pain treatment options that produce few or no .

Ken Hsu, a chemistry professor at the University of Virginia, and his graduate student, Myungsun Shin, has identified an enzyme that "chews up fat" molecules to produce chemical signals that control inflammation.

The naturally occurring enzyme, called diacylglycerol lipase-beta, or DAGL-beta, is a possible new drug target for reducing pain. Hsu developed, during his postdoctoral training, selective molecules that inhibit DAGL-beta and reduce inflammation, similarly to aspirin and other non-steroidal anti-inflammatory drugs, or NSAIDS. However, unlike NSAIDs, DAGL-beta inhibitors can provide without gastrointestinal toxicity in preclinical models when used over a long term. And unlike opioids, DAGL-beta inhibitors do not exhibit addictive properties.

"This could be a new route to treating long-term inflammation and pain without the side effects of toxicity and risk of addiction observed with current treatment options," Hsu said. "Generally, if we block inflammation, we also affect the . But we're suggesting a different approach, one where we can stop inflammation without impacting the normal immune response."

Hsu's findings were published today in the online edition of the journal Cell Chemical Biology.

According to Hsu, studies at UVA in collaboration with Virginia Commonwealth University demonstrate that DAGL-beta inhibitors are highly effective at reducing different pain states, including neuropathic pain and chemotherapy-induced peripheral neuropathy.

In the new study, the Hsu lab uncovered a new role for DAGL-beta in , a specialized type of innate immune cell that not only controls inflammation, but can also activate our body's ability to fight infections by stimulating T cells, which produce an immune response.

"We found that by blocking DAGL-beta, we can stop inflammation without affecting immunity," Hsu said. "This supports the idea that DAGL-beta is a viable target for long-term blockade of inflammation and pain without potentially compromising our ."

Hsu's research program is focused on using chemistry to find new ways to modulate the immune system, whether for fighting cancer, or, in this case, a better understanding of molecular pathways that can be targeted to reduce chronic and pain.


Explore further

New inhibitors of elusive enzymes promise to be valuable scientific tools

More information: Myungsun Shin et al, Diacylglycerol Lipase-β Is Required for TNF-α Response but Not CD8+ T Cell Priming Capacity of Dendritic Cells, Cell Chemical Biology (2019). DOI: 10.1016/j.chembiol.2019.04.002
Journal information: Cell Chemical Biology

Citation: Chemists ID possible addiction-free pain reliever (2019, May 16) retrieved 21 May 2019 from https://phys.org/news/2019-05-chemists-id-addiction-free-pain-reliever.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
65 shares

Feedback to editors

User comments

May 17, 2019
Lets hope they actually develop something. Because of losers predisposed to addiction, people who suffer pain are suffering even more because of the increased strictures placed on opioids because of these pathetic addicts. As usual, a majority are suffering because of a minority of useless people.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more